Patent ID: 9653272
Date: 2017-05-16
CPC Classifications: A61K,A61P,G01N,G16B,G16H,H01J,Y02A

Claim:
1. A method of predicting whether a cancer patient is likely to benefit from administration of a yeast-based immune response generating therapy for cancer, either alone or in addition to another anti-cancer therapy, comprising the steps of: (a) obtaining a blood-derived sample of the patient; (b) conducting mass-spectrometry on the sample and obtaining a mass spectrum from the sample, wherein the mass spectrometry comprises conducting MALDI-TOF mass spectrometry in which the blood-derived sample is subject to more than 20,000 laser shots; (c) in a programmed computer, performing one or more predefined pre-processing steps on the mass spectrum, obtaining integrated intensity values of selected features in the mass spectrum over predefined m/z ranges after the pre-processing steps are performed, and comparing the integrated intensity values with a training set comprising class-labeled spectra from other cancer patients and classifying the mass spectrum with a class label; wherein the class label predicts whether the patient is likely to benefit from the yeast-based immune response generating therapy, either alone or in addition to other anti-cancer therapies.